N. Moore

5.3k citations

27 papers · 4.0k indexed · 2 hit papers · h-index 16

Impact in

Cancer Research top 1%
- Cancer Genomics and Diagnostics
Pulmonary and Respiratory Medicine top 0.5%
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations

Papers in ⓘ

Pulmonary and Respiratory Medicine 17
- Lung Cancer Treatments and Mutations 6
- Renal cell carcinoma treatment 5
- Brain Metastases and Treatment 4
Oncology 16
- Cancer Treatment and Pharmacology 10
- Colorectal Cancer Treatments and Studies 8

Co-authors: Cezary Szczylik (5 shared papers)Alain Ravaud (6 shared papers)Bernard Escudier (5 shared papers)Natasha B. Leighl (6 shared papers)Sergio Bracarda (5 shared papers)M. Filipek (4 shared papers)Bohuslav Melichar (4 shared papers)A Płużańska (4 shared papers)
Journals: Journal of Clinical Oncology (10 papers)British Journal of Cancer (1 paper)Journal of Thoracic Oncology (1 paper)The Lancet (1 paper)BMC Geriatrics (1 paper)
Partner nations: Switzerland Germany France

In The Last Decade

N. Moore

27 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL 2009 · 1.2k citations

Peers

Countries citing papers authored by N. Moore

Since Specialization

Citations

This map shows the geographic impact of N. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Moore more than expected).

Fields of papers citing papers by N. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Moore. The network helps show where N. Moore may publish in the future.

Co-authors

The 25 scholars most cited alongside N. Moore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with N. Moore Line = papers co-authored together N. Moore links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial The Lancet ·Bernard Escudier, A Płużańska, P. Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, Emilio Bajetta, В. А. Горбунова, Jacques‐Olivier Bay, I. Bodrogi, Agnieszka Jagiełło-Gruszfeld, N. Moore Hit paper breakdown →	2007	1722
2	Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL Journal of Clinical Oncology ·Martin Reck, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, Vera Gorbounova, Vera Hirsh, Natasha B. Leighl, J. Mezger, Venice Archer, N. Moore, Christian Manegold Hit paper breakdown →	2009	1174
3	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial Journal of Clinical Oncology ·Thomas Sandmann, Richard Bourgon, Josep Garcia, Congfen Li, Timothy F. Cloughesy, Olivier Chinot, Wolfgang Wick, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Albert Lai, N. Moore, Samir Kharbanda, Franklin Peale, Priti S. Hegde, Lauren E. Abrey, Heidi Phillips, Carlos Bais	2015	208
4	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer Journal of Clinical Oncology ·Luca Gianni, Gilles Romieu, М. Р. Личиницер, Sérgio Serrano, Mauro Mansutti, Xavier Pivot, Paola Mariani, Fabrice André, Arlene Chan, Oleg Lipatov, Stephen Chan, Andrew Wardley, Richard Greil, N. Moore, Sylvie Prot, Céline Pallaud, Semiglazov Vf	2013	199
5	AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme Advances in Therapy ·Olivier Chinot, T. De La Motte Rouge, N. Moore, Ali Zeaiter, Arabinda K. Das, Heidi Phillips, Zora Modrušan, Timothy F. Cloughesy	2011	149
6	A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma Journal of Clinical Oncology ·Bernard Escudier, P. Koralewski, A Płużańska, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, N. Moore	2007	85
7	Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL) Journal of Thoracic Oncology ·Natasha B. Leighl, Petr Zatloukal, J. Mezger, Rodryg Ramlau, N. Moore, Martin Reck, Christian Manegold	2010	82
8	R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes Haematologica ·John F. Seymour, M Pfreundschuh, Marek Trněný, Laurie H. Sehn, J. Catalano, Eva Csinady, N. Moore, Bertrand Coiffier, (unknown)	2014	76
9	Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study British Journal of Cancer ·Natasha B. Leighl, Jaafar Bennouna, Yi Jiang, N. Moore, J. Hambleton, Herbert I. Hurwitz	2011	43
10	Do the malnutrition universal screening tool (MUST) and Birmingham nutrition risk (BNR) score predict mortality in older hospitalised patients? BMC Geriatrics ·Sarah B. Henderson, N. Moore, Emma Lee, Miles D. Witham	2008	43
11	Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial Asia-Pacific Journal of Clinical Oncology ·Tony Mok, Te‐chun Hsia, Chun-Ming Tsai, Kenneth W.T. Tsang, Gee-Chen Chang, John Wen-Cheng Chang, T. Sirisinha, Virote Sriuranpong, Sumitra Thongprasert, Daniel T. T. Chua, N. Moore, Christian Manegold	2011	37
12	S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC) Cancer Research ·Luca Gianni, Gilles Romieu, M. Lichinitser, Sérgio Serrano, Mauro Mansutti, Xavier Pivot, И А Смирнова, Angela Moliterni, Fabrice André, Arlene Chan, Oleg Lipatov, Sze Wah Samuel Chan, Andrew Wardley, Richard Greil, Louise Provencher, N. Moore, Sylvie Prot, Semiglazov Vf	2011	29
13	Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology ·E. Bajetta, Alain Ravaud, Sergio Bracarda, Sylvie Négrier, Cezary Szczylik, Joaquim Bellmunt Molins, N. Moore, Pavel Pisa, Bernard Escudier	2008	18
14	Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications). Journal of Clinical Oncology ·Carlos Bais, Christina Rabe, Norbert Wild, Magdalena Lange, David Chen, Kyu Hong, Lukas C. Amler, N. Moore, Priti S. Hegde	2014	17
15	Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]). Journal of Clinical Oncology ·Heidi Phillips, Thomas Sandmann, Congfen Li, Timothy F. Cloughesy, Olivier Chinot, Wolfgang Wick, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Albert Lai, N. Moore, Priti S. Hegde, Lauren E. Abrey, Richard Bourgon, Josep Garcia, Carlos Bais	2014	16
16	Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL) Journal of Clinical Oncology ·N. B. Leighl, Petr Zatloukal, J. Mezger, Rodryg Ramlau, V.R. Archer, N. Moore, Martin Reck	2009	15
17	AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology ·Olivier Chinot, Wolfgang Wick, Frank Saran, Warren Mason, Roger Henriksson, Ryo Nishikawa, Ali Zeaiter, N. Moore, Arabinda K. Das, Timothy F. Cloughesy	2011	11
18	4518 POSTER First-line bevacizumab improves progression-free survival with lower doses of interferon-a2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN) European Journal of Cancer Supplements ·Bohuslav Melichar, P. Koralewski, A Płużańska, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, N. Moore, Bernard Escudier	2007	8
19	Hypermobility, developmental coordination disorder and physical activity in an Irish paediatric population Musculoskeletal Care ·N. Moore, S. Rand, Jane Simmonds	2019	8
20	6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) European Journal of Cancer Supplements ·C. Manegold, J. vonPawel, Petr Zatloukal, Rodryg Ramlau, Vera Gorbounova, Vera Hirsh, Natasha B. Leighl, J. Mezger, N. Moore, Martin Reck	2007	7

About N. Moore

N. Moore is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Genetics and Surgery, having authored 27 papers that have together received 4.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (6 papers), Glioma Diagnosis and Treatment (6 papers), Renal cell carcinoma treatment (5 papers), Cancer Genomics and Diagnostics (5 papers), Brain Metastases and Treatment (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). The work is most often cited by research in Cancer Research (1.2k citations), Pulmonary and Respiratory Medicine (2.6k citations), Oncology (2.0k citations), Genetics (460 citations) and Molecular Biology (1.7k citations). N. Moore has collaborated with scholars based in Switzerland, Germany and France. Frequent co-authors include Cezary Szczylik, Alain Ravaud, Bernard Escudier, Natasha B. Leighl, Sergio Bracarda, M. Filipek, Bohuslav Melichar, A Płużańska, P. Koralewski and Christine Chevreau. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Journal of Thoracic Oncology, The Lancet and BMC Geriatrics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact